Palvella Therapeutics Inc PVLA

$146.58 +2.23 (1.54%)

Valuation

Market cap
2,110,109,000
Revenue TTM
$0
Net income TTM
$-41,720,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
118,900
Avg volume
254,824
Day's range
$143.90 – $148.42
Shares out
14,618,000
Stochastic %K
15%
Beta
-0.21
Analysts
Strong Buy
Price target
$230.88

Price

Company profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat...

Show more

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
484 253 1461
Website
https://palvellatx.com
Address
353 W. Lancaster Avenue, Suite 200, Wayne, United States

Latest news

Stocktwits

prismmarketview Nov 19, 1:53 PM
$PVLA Palvella unveils QTORIN™ docetaxel, a topical first-line program for Extramammary Paget’s Disease. EMPD is a rare skin cancer with no FDA-approved therapy, and an estimated 10,000+ U.S. patients have it. FDA meeting planned for 1H 2027, then Phase 2. https://prismmarketview.com/palvella-unveils-qtorin-docetaxel-aiming-for-the-first-fda-approved-therapy-in-rare-skin-cancer-empd/
0 replies
notreload_ai Nov 16, 2:46 PM
$ZYME: $200M buyback (~$140M by 2028) to lift returns while funding R&D & deals. $RPID: Merck KGaA buyout at $0.75/share cash (close Dec 2026); automates pharma microbe testing. $PVLA: Leerink Outperform $228 PT—QTORIN path solid, FDA Feb 2027, platform ready. https://notreload.xyz/wall-street-live-monday-november-16/
0 replies
Eagley3k Nov 12, 4:28 AM
$PVLA exited $175. cant be gready everyday.
0 replies
GTA_Terminal Nov 8, 10:54 PM
Dark pool check on $PVLA: what traded off the exchanges in the latest session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PVLA&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PVLA Read the full article for the full details: https://globaltradersacademy.com/articles/palvella-pvla-technical-levels-options-flow-dark-pools-line-up-above-143?utm_source=stocktwits&utm_medium=social
0 replies
GTA_Terminal Nov 7, 5:25 AM
Dark pool check on $PVLA: what traded off the exchanges this session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PVLA&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PVLA Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-activity-unusual-off-exchange-trading-in-palvella-therapeutics-pvla?utm_source=stocktwits&utm_medium=social
0 replies
JamesAnthonyR Nov 6, 5:38 PM
$PVLA anyone still here from the original $PIRS stock? What a journey it’s been on this one
2 replies
STRelativeStrength Nov 6, 4:50 PM
$PVLA undiscovered breakout with 291 watchers
0 replies
EarningsInsider Nov 5, 2:46 PM
https://www.marketbeat.com/earnings/reports/2026-11-5-palvella-therapeutics-stock/ $PVLA Palvella Therapeutics Earnings Transcript
0 replies